Electrochemically activated chemotherapy (EAC) works in the oncological clinic thanks to intratumor injection (ITI): a surgical technique that once only relied on the surgical team's anatomical knowledge, and has found itself more-and-more success in today's world thanks to the half-century of advances in imaging hardware and software.

​

Clinical outcomes that use ITI as a means of supportive oncological intervention have improved prognoses post-surgery, and most ITI surgeries are minimally invasive for faster recovery times. Often very well tolerated by sensitive or compassionate care patients: ITI is highly compatible with existing oncological treatment regimes, offering direct-to-tumor deposition of potent anticancer agents, and ITI is also able to lessen systemic effects versus comparative standards of care. 

​

ITI is high precision surgical medicine.​

​

EAC is built upon these precision surgery clinical successes because EAC is a specialty form of ITI, one that utilizes an extra layer of molecular protection and chemical sophistication in the design and development of its CGP-activatable chemotherapies.

While I personally like ITI, it's not without its risks, and all of these anti-cancer tools and techniques available are situationally specific and applicably unique to each person, with that being said:

With EAC as ITI you can now precisely control where, when, and how much of an active metabolite of a cytotoxic pharmacological molecule, not just the parent compound, ​is applied directly inside of a problematic cancerous tumor.

​​

EAC as ITI is a scientific physical limit technology, meaning: additional technological or conceptual advancements will begin overlapping with other preexisting forms of clinical cancer treatment like ionizing radiation, chemical chemotherapy, surgery, and or photodynamic therapy.

​

EAC as ITI is the End Game in surgical, molecular, and robotic oncological treatment control.​​

 

You can get different options, but you can't get any better!